Ashok Sebastian Komaranchath, Consultant Medical Oncology and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared on LinkedIn:
“Moderating my first session in a major oncology conference in the Middle East, the 6th EOS Conference at Dubai, UAE.
I found it fitting to be part of this session on Gynaec-oncology in this month of September which is gyneacological cancer awareness month.
2025 seems to be the year of ADCs with mirvetuximab soravtansine becoming a game changer in platinum resistant ovarian cancer.”
Read more posts featuring Ashok Sebastian Komaranchath on OncoDaily.